Ropivacaine

Ropivacaine

File:Ropivacaine.png
Clinical data
Pregnancy category	AU: B1
Routes of administration	Parenteral
ATC code	N01BB09 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)
Pharmacokinetic data
Bioavailability	87%–98% (epidural)
Metabolism	Hepatic (CYP1A2-mediated)
Elimination half-life	1.6–6 hours (varies with administration route)
Excretion	Renal 86%
Identifiers
IUPAC name (S)-N-(2,6-dimethylphenyl)- 1-propylpiperidine-2-carboxamide
CAS Number	84057-95-4
PubChem CID	175805
DrugBank	APRD00492
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H26N2O
Molar mass	274.4 g/mol

WikiDoc Resources for Ropivacaine
Articles
Most recent articles on Ropivacaine Most cited articles on Ropivacaine Review articles on Ropivacaine Articles on Ropivacaine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ropivacaine Images of Ropivacaine Photos of Ropivacaine Podcasts & MP3s on Ropivacaine Videos on Ropivacaine
Evidence Based Medicine
Cochrane Collaboration on Ropivacaine Bandolier on Ropivacaine TRIP on Ropivacaine
Clinical Trials
Ongoing Trials on Ropivacaine at Clinical Trials.gov Trial results on Ropivacaine Clinical Trials on Ropivacaine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ropivacaine NICE Guidance on Ropivacaine NHS PRODIGY Guidance FDA on Ropivacaine CDC on Ropivacaine
Books
Books on Ropivacaine
News
Ropivacaine in the news Be alerted to news on Ropivacaine News trends on Ropivacaine
Commentary
Blogs on Ropivacaine
Definitions
Definitions of Ropivacaine
Patient Resources / Community
Patient resources on Ropivacaine Discussion groups on Ropivacaine Patient Handouts on Ropivacaine Directions to Hospitals Treating Ropivacaine Risk calculators and risk factors for Ropivacaine
Healthcare Provider Resources
Symptoms of Ropivacaine Causes & Risk Factors for Ropivacaine Diagnostic studies for Ropivacaine Treatment of Ropivacaine
Continuing Medical Education (CME)
CME Programs on Ropivacaine
International
Ropivacaine en Espanol Ropivacaine en Francais
Business
Ropivacaine in the Marketplace Patents on Ropivacaine
Experimental / Informatics
List of terms related to Ropivacaine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ropivacaine (rINN) (Template:PronEng) is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin.

History

Ropivacaine was developed after bupivacaine was noted to be associated with cardiac arrest in 0.5–0.75% of cases, particularly in pregnant women. Ropivacaine was found to have less cardiotoxicity than bupivacaine in animal models.

Clinical use

Indications

Ropivacaine is indicated for local anaesthesia including infiltration, nerve block, epidural and intrathecal anaesthesia in adults and children over 12 years. It is also indicated for peripheral nerve block and caudal epidural in children 1–12 years for surgical pain. It is also sometimes used for infiltration anaesthesia for surgical pain in children.

Ropivacaine is often co-administered with fentanyl for epidural analgesia, for example in pregnant women during labour.

Contraindications

Ropivacaine is contraindicated for IV regional anaesthesia (IVRA).

Adverse effects

Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.

Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.

Treatment of overdose: "Lipid rescue"

As for bupivacaine, there is evidence that Intralipid, a commonly available intravenous lipid emulsion, can be effective in treating severe cardiotoxicity secondary to local anaesthetic overdose in animal experiments and in humans.